

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 86248

Title: Baseline metabolites could predict the responders with HBV-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03647881

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Attending Doctor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2023-06-08

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-11 05:27

Reviewer performed review: 2023-07-14 23:27

Review time: 3 Days and 17 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

No comments.

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 86248

Title: Baseline metabolites could predict the responders with HBV-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04072104

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Doctor, Doctor, Occupational Physician, Research Scientist

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2023-06-08

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-25 07:43

Reviewer performed review: 2023-08-02 12:48

Review time: 8 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

It is an interesting manuscript about “Baseline metabolites could predict the responders with HBV-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet”

My concern is determined in the following points. There is a lack of sensitive and specific objective method to determine the necroinflammation and fibrosis stages in CHB patients. Accurate and noninvasive diagnosis and staging of liver fibrosis are essential for effective clinical management of chronic hepatitis B. 4-metabolite panel has potential usefulness in clinical assessments of chronic liver disease progression in patients with chronic hepatitis B virus infection. The proposed metabolomic biosignature has the potential to be used as indicator for antiviral treatment for chronic hepatitis B management. There was no single FZHY groups. The selected differential metabolites and metabolism pathways of findings need to be further verified in terms of HBV-related liver fibrosis patients with response to FZHY treatment alone. Above mentioned factors should be referred to.